

### AMENDMENTS TO THE CLAIMS

1. (Previously presented) An isolated peptide with an amino acid sequence consisting of 8-40 amino acids and comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-66, wherein the peptide binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

2. (Currently amended) The isolated peptide according to claim 1, wherein the peptide comprises~~further comprising~~ amino- and carboxy-terminal cysteine residues.

3.-11. (Cancelled)

12. (Previously presented) The isolated peptide according to claim 1, comprising the amino acid sequence set forth in any one of SEQ ID NOs: 35-43 and 55-66.

13. (Original) The isolated peptide of claim 1, wherein said peptide comprises the sequence CGYWLTIWGC (SEQ ID NO: 35).

14.-23. (Cancelled)

24. (Previously presented) An isolated peptide according to claim 1, 78, or 82, wherein said peptide further comprises an intramolecular bond between amino acid residues to form a cyclic peptide.

25. (Previously presented) The isolated peptide according to claim 24, wherein the peptide comprises amino- and carboxy-terminal cysteines, and the intramolecular bond comprises a disulfide bond between the cysteines.

26. (Previously presented) The isolated peptide according to claim 1, 78, or 82, wherein said peptide inhibits Vascular Endothelial Growth Factor C (VEGF-C) binding to the human VEGFR-3.

27. (Previously presented) The isolated peptide according to claim 1, 78, or 82, further comprising a cytotoxic agent, or a label attached to the peptide.

28. (Previously presented) The peptide according to claim 27, wherein the cytotoxic agent comprises a radioisotope.

29. (Previously presented) The peptide according to claim 27, wherein the cytotoxic agent comprises an anti-neoplastic pro-drug.

30. (Previously presented) A chimeric protein comprising a therapeutic protein amino acid sequence attached to the amino acid sequence of a peptide according to claim 1, 78, or 82.

31. (Previously presented) The chimeric protein according to claim 30, wherein the therapeutic protein comprises a tumor necrosis factor.

32. (Previously presented) The peptide according to claim 1, 78, or 82 attached to an antibody or fragment thereof.

33. (Previously presented) The isolated peptide of claim 1, 78, or 82, wherein said peptide further comprises a modification to increase the circulating *in-vivo* half-life of the peptide in a mammal.

34. (Cancelled)

35. (Previously presented) A peptide dimer comprising first and second peptides according to claim 1, 78, or 82.

36. (Currently amended) The peptide dimer according to claim 35, wherein the first and second peptides comprise the same amino acid sequence~~peptide~~.

37. (Cancelled)

38. (Previously presented) A composition comprising an isolated peptide according to claim 1, 78, or 82 in a pharmaceutically acceptable carrier.

39.-74. (Cancelled)

75. (Previously presented) The peptide of claim 27 wherein the label is selected from the group consisting of a radionuclide, a dye, an enzyme, and an enzyme substrate.

76. (Previously presented) The peptide of claim 1, 78, or 82 with an amino acid sequence consisting of 8-25 amino acids.

77. (Previously presented) The peptide of claim 12 or claim 13 with an amino acid sequence consisting of 10-25 amino acids.

78. (Previously presented) An isolated peptide with an amino acid sequence consisting of 8-40 amino acids and comprising the amino acid sequence set forth in SEQ ID NO: 34, wherein the peptide binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

79. (Currently amended) The isolated peptide according to claim 78, wherein the peptide comprises~~further comprising~~ amino- and carboxy-terminal cysteine residues.

80. (Previously presented) The isolated peptide of claim 78 with an amino acid sequence consisting of 8-35 amino acids.

81. (Previously presented) The isolated peptide of claim 80 with an amino acid sequence consisting of 10-30 amino acids.

82. (Previously presented) An isolated peptide with an amino acid sequence consisting of 8-40 amino acids and comprising the amino acid sequence spanning amino acid residue 2 through amino acid residue 9 of any one of SEQ ID NOs: 35 and 55-58, wherein the peptide binds to human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3).

83. (Currently amended) The isolated peptide according to claim 82, wherein the peptide comprises~~further comprising~~ amino- and carboxy-terminal cysteine residues.

84. (Previously presented) The isolated peptide of claim 82 with an amino acid sequence consisting of 8-35 amino acids.

85. (Previously presented) The isolated peptide of claim 84 with an amino acid sequence consisting of 10-30 amino acids.